Table 3.
Baseline characteristics of trial subjects with chronic kidney disease
| Characteristic | AMIST (n=18) | BARI (n=43) | Cisowski (n=11) | ERACI II (n=111) | GABI (n=51) | Le MANS (n=16) | Leipzig (n=30) | MASS 1 (n=25) | MASS 2 (n=83) | VA (n=138) |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, years mean (SD) | 64.3 (8.9) | 63.9.(8.8) | 62.3 (10.0) | 64.6 (9.4) | 64.3 (7.0) | 68.0 (8.3) | 68.7 (7.2) | 61.8 (9.4) | 66.2 (6.5) | 72.2 (6.6) |
| Male | 11 (61.1) | 31 (72.1) | 7 (63.6) | 44 (39.6) | 26 (51.0) | 7 (43.8) | 16 (53.3) | 8 (32.0) | 3 (63.9) | 136 (98.6) |
| White | 18 (100.0) | 33 (76.7) | 11 (100.0) | 111 (100.0) | 51 (100.0) | 16 (100.0) | 30 (100.0) | 25 (100.0) | 76 (91.6) | 122 (88.4) |
| Stage 3b-5 CKD | 4 (22.2) | 23 (53.5) | 4 (36.4) | 14 (12.6) | 11 (21.6) | 5 (31.3) | 4 (13.3) | 4 (16.0) | 18 (21.7) | 50 (36.2) |
| Stage 4-5 CKD, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.9) | 4 (7.6) | 1 (6.3) | 0 (0.0) | 0 (0.0) | 4 (4.8) | 10 (7.0) |
| eGFR mL/min/1.73m2, mean (SD) | 49.8 (8.1) | 43.0 (6.7) | 48.3 (8.1) | 50.1 (6.6) | 49.7 (11.4) | 46.9 (8.4) | 53.1 (6.5) | 52.0 (6.7) | 49.0 (10.4) | 46.9 (10.6) |
| Diabetes | -- | 20 (46.5) | 3 (27.3) | 22 (19.8) | 8 (15.7) | 6 (37.5) | 15 (5.7) | 5 (20.0) | 25 (30.1) | 40 (29.0) |
| Smoking | -- | 7 (16.3) | 3 (27.3) | 50 (45.1) | 3 (5.9) | 1 (6.7) | 4 (13.8) | 7 (28.0) | 14 (16.9) | 20 (20.2) |
| Hypertension | -- | 33 (76.7) | 8 (72.7) | 91 (82.0) | 32 (62.8) | 16 (93.8) | 28 (96.6) | 7 (28.0) | 58 (69.9) | 113 (81.9) |
| Hyperlipidemia | -- | 18 (48.7) | 5 (45.5) | 72 (64.9) | 36 (70.6) | 16 (100.) | 18 (62.1) | 19 (76.0) | 61 (73.5) | -- |
| Prior revascularization | -- | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (25.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 49 (35.5) |
| Prior MI | -- | 24 (57.1) | 2 (18.2) | 31 (27.9) | 27 (54.0) | 11 (68.8) | 17 (58.6) | 0 (0.0) | 38 (45.8) | 93 (68.4) |
| CHF | -- | 14 (32.6) | 0 (0.0) | 2 (1.8) | 30 (58.8) | 0 (0.0) | -- | 0 (0.0) | 2 (2.4) | 108 (88.5) |
| Multi-vessel disease | 0 (0.0) | 42 (97.7) | 0 (100.0) | 111 (100.0) | 51 (100.0) | 16 (100.0) | 30 (0.0) | 0 (0.0) | 83 (100.0) | 116 (84.1) |
| Left main disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (4.5) | 0 (0.0) | 16 (100.0) | 0 (0.0) | 0 (0.0) | 0 (.0.0) | 12 (8.9) |
| Proximal LAD disease | 18 (100.0) | 27 (62.8) | 11 (100.0) | 59 (53.2) | 14 (27.5) | 8 (50.0) | 30 (100.0) | 25 (100.0) | 78 (94.0) | 69 (51.1) |
| No. diseased vessels, mean (SD) | 1 (0.0) | 2.6 (0.5) | 1 (0.0) | 2.6 (0.5) | 2.4 (0.5) | 3.3 (0.8) | 1.2 (0.4) | 1 (0.0) | 2.6 (0.5) | 2.3 (0.8) |
| Ejection Fraction, %, mean (SD) | 61.3 (14.1) | 54.5 (12.5) | 58.1 (5.9) | 52.8 (5.3) | 64.1 (11.1) | 54.1 (5.0) | 62.6 (13.5) | 69.3 (3.2) | 67.5 (9.2) | 45.4(14.7) |
| Elevated cardiac biomarkers on admission | -- | -- | 0 (0.0) | 29 (26.1) | 0 (0.0) | 1 (6.3) | 0 (0.0) | -- | 0 (0.0) | -- |
| MI on admission | 0 (0.0) | 1 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (6.3) | 0 (0.0) | 0 (0.0) | 38 (45.8) | 40 (29.0) |
| Unstable angina on admission | 3 (16.7) | 32 (74.4) | 1 (9.1) | 104 (93.7) | 10 (20.0) | 11 (68.8) | 6 (20.0) | 0 (0.0) | 0 (0.0) | -- |
Table 1-Baseline characteristics. Data are presented as n (%) unless otherwise noted. eGFR estimates for BARI were calculated as described in the methods. CKD-chronic kidney disease, CHF-congestive heart failure, LAD-left anterior descending artery, MI-myocardial infarction, No-number, SD-standard deviation. Data on diabetes was not available for subjects in AMIST. Data on smoking was not available in AMIST, and was missing for 1 subject in LE MANS, and 39 subjects in the VA study. Hyperlipidemia was missing all AMIST subjects, 6 in BARI, 1 in Leipzig, and all VA subjects. Data on baseline hypertension was unavailable in AMIST and was missing for 1 subject from Leipzig. Prior revascularization was unavailable for AMIST. Prior MI was unavailable for AMIST, and was missing in 1 subject from BARI, 1 subject from GABI, 1 in Leipzig, and 2 in the VA study. CHF was not available for AMIST participants and was missing in 16 subjects from the VA study. Data on left main disease was missing in 3 VA subjects. Proximal LAD was missing in 3 subjects in the VA study. Data on number of diseased vessels was missing in 3 subjects from the VA study. Ejection fraction was missing in 10 subjects in AMIST, 23 in GABI, 1 in Le MANS and 33 in the VA study. Cardiac biomarkers at baseline were not available for AMIST, BARI, VA, and MASS 1 studies. Unstable angina at admission was missing in 1 subject from GABI, and all subjects in the VA study.